Potential evaluation of the incremental cost-effectiveness of paclitaxel in advanced non-small-cell lung cancer (Eastern Cooperative Oncology Group 5592)
Potential evaluation of the incremental cost-effectiveness of paclitaxel in advanced non-small-cell lung cancer (Eastern Cooperative Oncology Group 5592)(English)